Targeting LAG-3 to Potentiate Antitumor Immune Activity: Expert Guidance on Molecular Function and Clinical Application

This series of live workshops will cover the importance of LAG-3 as a new immunotherapy target and the emerging data on the mechanism of action use and safety of anti&ndash LAG-3 immunotherapies across a range of malignancies. Accompanying these workshops will be a downloadable slideset simulcasts an expert commentary a PDF practice resource and an on-demand webcast.

Live webinars!

Webinar 1 - June 28 2022

Webinar 2 - July 6 2022

Webinar 3 - July 19 2022

 

Share

Program Content

No activities added yet

Activities

Rela/Nivo 1L Melanoma
What to Know About the Novel Anti–LAG-3 Checkpoint Inhibitor Relatlimab in Melanoma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 21, 2022

Expires: March 20, 2023

Activities

Targeting LAG-3 in Cancer
Targeting LAG-3 to Potentiate Antitumor Immune Activity: Expert Guidance on Molecular Function and Clinical Application
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 23, 2022

Expires: March 22, 2023

<i>ExpressPoints</i>: LAG-3 Mechanism of Action
ExpressPoints
LAG-3 Mechanism of Action
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2022

Expires: March 21, 2023

Activities

LAG-3 Summary Resource
Understanding the Role of LAG-3 in Malignancies: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: March 23, 2022

Expires: March 22, 2023

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb